Avaliação dos tumores adrenais e análise do perfil metabólico de pacientes com incidentaloma
Evaluation of adrenal tumors and analysis of the metabolic profile of patients with incidentaloma
Pedro Victor Gonçalves Montalvão; Iuri Moura Mangueira; Gabriel da Motta Alves; João Vitor Fazzio Cordeiro; Marcia Helena Soares Costa; Guilherme de Andrade Gagheggi Ravanini
Resumo
Introdução: O avanço nos métodos de imagem tem levado a um diagnóstico cada vez mais frequente de lesões das glândulas adrenais como achado incidental. Apesar dos progressos nessa área, ainda há pouca informação sobre a epidemiologia do perfil clínico e metabólico de pacientes com incidentaloma das glândulas adrenais (IG). O objetivo deste estudo é analisar a epidemiologia dos tumores adrenais do Hospital Universitário Gaffrée e Guinle (HUGG) e comparar com os dados da literatura.
Método: Trata-se de um estudo transversal em que foram incluídos pacientes de qualquer sexo e idade atendidos no HUGG com tumores em adrenais.
Resultados: Foram avaliadas as seguintes variáveis: idade, sexo, funcionalidade, benignidade e tamanho. Analisamos também o perfil metabólico de pacientes com IA e mais especificamente daqueles com autonomia de secreção do cortisol. De 31 pacientes com tumores de adrenal, 68% eram do sexo feminino. A idade média foi de 55 anos com desvio padrão de 16,2. 54% da amostra eram incidentalomas de adrenais. 93.6% da amostra eram casos benignos. Dos incidentalomas de adrenal, 53% eram não secretores. Nos pacientes com tumores de adrenal apenas 10% apresentaram síndrome metabólica enquanto que nos pacientes com secreção autônoma de cortisol esse número subiu para 17%.
Conclusão: A amostra de pacientes com tumores de adrenal e incidentaloma no HUGG apresentou uma prevalência de complicações metabólicas similares com a encontrada na literatura.
Palavras-chave
Abstract
Introduction: Advances in imaging methods have led to an increasingly frequent diagnosis of adrenal gland lesions as incidental findings. Despite progress in this field, there is still limited information regarding the epidemiology of the clinical and metabolic profile of patients with adrenal incidentaloma (AI). The objective is analyze the epidemiology of adrenal tumors at Gaffrée e Guinle University Hospital (HUGG) and compare it with data from the literature.
Method: This is a cross-sectional study that included patients of any gender and age who was treated at HUGG for adrenal tumors.
Results: The following variables were evaluated: age, gender, functionality, benignity, and size. We also analyzed the metabolic profile of patients with AI, specifically those with mild autonomy cortisol secretion. Out of 31 patients with adrenal tumors, 68% were female. The mean age was 55 years with a standard deviation of ±16.2. 54% of the sample had adrenal incidentalomas. 93.6% of the sample had benign cases. Among the adrenal incidentalomas, 53% were non-functioning. In patients with adrenal tumors, only 10% had metabolic syndrome, while in patients with mild autonomous cortisol secretion, this number rose to 17%.
Conclusion: The sample of patients with adrenal tumors and incidentaloma at HUGG presented a prevalence of metabolic complications similar to that found in the literature.
References
1 Kapoor A, Morris T, Rebello R. Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J. 2011;5(4):241-7. doi: 10.5489/cuaj.11135.
2 Aron D, Terzolo M, Cawood T. Adrenal incidentalomas. Best Pract Res Clin Endocrinol Metab. 2012;26(1):69-82. doi: 10.1016/j.beem.2011.06.012.
3 Falcetta P, Orsolini F, Benelli E. et al. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study. Endocrine. 2021;71(1):178-88. doi: 10.1007/s12020-020-02476-1.
4 Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi: 10.1530/EJE-16-0467.
5 Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011 Jun;164(6):851-70. doi: 10.1530/EJE-10-1147.
6 Grumbach MM, Biller BMK, Braunstein GD, Campbell KK, Carney JA. (2003). NIH Conference Management of the Clinically Inapparent Adrenal Mass. Ann Intern Med. 2003;138(5):424-9. doi: 10.7326/0003-4819-138-5-200303040-00013.
7 Mayo-Smith WW, Song JH, Boland GL, Francis IR, Israel GM, et al. Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(8):1038-44. doi: 10.1016/j.jacr.2017.05.001.
8 Zografos GN, Perysinakis I, Vassilatou E. Subclinical Cushing's syndrome: Current concepts and trends. Hormones (Athens). 2014;13(3):323-37. doi: 10.14310/horm.2002.1506.
9 Valli N, Catargi B, Ronci N, Vergnot V, Leccia, F, et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol. 2001;144(4):401-8. doi: 10.1530/eje.0.1440401.
10 Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513-27. doi: 10.1530/EJE-09-0234.
11 Care D, Suppl SS. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.
12 World Health Organization. Obesity: preventing and managing the global epidemic. Report of a World Health Organization Consultation. Geneva: World Health Organization. WHO Obesity Technical Report Series. 2000
13 Faludi A, Izar M, Saraiva J. Dislipidemias e Prevenção da Aterosclerose - 2017. Sociedade Brasileira de Cardiologia 2017. Arq Bras Cardiol. 2017;109(2,supl.1):1-90. doi: 10.5935/abc.20170121. Erratum in: Arq Bras Cardiol. 2017;109(5):499.
14 Santos CE, Schrank Y, Kupfer R. Critical analysis of WHO, IDF and NCEP criteria for metabolic syndrome among patients with type 1 diabetes mellitus. Arq Bras Endocrinol Metabol. 2009;53(9):1096-102. doi: 10.1590/s0004-27302009000900006.
15 Barzon L, Sonino N, Fallo F, Palù G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-85. doi: 10.1530/eje.0.1490273.
16 Guerrero MA, Schreinemakers JMJ, Vriens MR, Suh I, Hwang J, Shen WT, et al. Clinical Spectrum of Pheochromocytoma. J Am Coll Surg. 2009;209(6):727-32. doi: 10.1016/j.jamcollsurg.2009.09.022.
17 Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169(1):5-11. doi: 10.1016/S0022-5347(05)64023-2.
18 Tsentidis C, Bampilis A, Ntova V, Fragkos D, Panos C, Limniati C, et al. Metabolic Syndrome as a Predictor of Adrenal Functional Status: A Discriminant Multivariate Analysis Versus Logistic Regression Analysis. Horm Metab Res. 2019;51(1):47-53. doi: 10.1055/a-0754-6464.
19 Palmieri S, Morelli V, Polledri E, et al. The role of salivary cortisol measured by liquid chromatography- tandem mass spectrometry in the diagnosis of subclinical hypercortisolism. Eur J Endocrinol. 2013;168(3):289-96. doi: 10.1530/EJE-12-0803.
20 Toniato A, Merante-Boschin I, Opocher G, Pelizzo M, et al. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009;249(3):388-91. doi: 10.1097/SLA.0b013e31819a47d2.
21 Akaza I, Yoshimoto T, Iwashima F, et al. Clinical outcome of subclinical Cushing's syndrome after surgical and conservative treatment. Hypertens Res. 2011;34(10):1111-5. doi: 10.1038/hr.2011.90.
Submitted date:
11/09/2023
Accepted date:
08/18/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email